NCT05099965View on ClinicalTrials.gov

Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

November 8, 2024

Study Completion Date

October 14, 2025

Conditions
Cytomegalovirus InfectionsHIV InfectionsVaccine
Interventions
BIOLOGICAL

CMV-MVA Triplex

5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine

BIOLOGICAL

Placebo

7.5% Lactose in phosphate-buffered saline \[PBS\]

Trial Locations (12)

15213

University of Pittsburgh CRS, Pittsburgh

19104

Penn Therapeutics, CRS, Philadelphia

27599

Chapel Hill CRS, Chapel Hill

35222

Alabama CRS, Birmingham

44106

Case Clinical Research Site, Cleveland

63110

Washington University Therapeutics (WT) CRS, St Louis

77009

Houston AIDS Research Team CRS, Houston

80045

University of Colorado Hospital CRS, Aurora

92103

UCSD Antiviral Research Center, San Diego

94110

Ucsf Hiv/Aids Crs, San Francisco

90035-4709

UCLA CARE Center CRS, Los Angeles

02114

Massachusetts General Hospital CRS (MGH CRS), Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH